Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer.

about

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models.

P2860

Q54981847-158A43F9-300B-4588-BC33-84ACB767C828

P2860

Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer.

Item

http://www.wikidata.org/entity/Q42660638

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer.

@en

Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer.

@nl

type

Item

label

Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer.

@en

Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer.

@nl

prefLabel

Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer.

@en

Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer.

@nl

P1476

Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer.

@en

P2093

Donghai Xiong

http://www.w3.org/2001/XMLSchema#string

Jiaqi Hu

http://www.w3.org/2001/XMLSchema#string

Jing Pan

http://www.w3.org/2001/XMLSchema#string

Mark Steven Miller

http://www.w3.org/2001/XMLSchema#string

Ming You

http://www.w3.org/2001/XMLSchema#string

Qi Zhang

http://www.w3.org/2001/XMLSchema#string

Ronald A Lubet

http://www.w3.org/2001/XMLSchema#string

Ruichao Li

http://www.w3.org/2001/XMLSchema#string

Sang Beom Lee

http://www.w3.org/2001/XMLSchema#string

Xu Chen

http://www.w3.org/2001/XMLSchema#string

P2860

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship

Epidermal growth factor-related peptides and their receptors in human malignancies

Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera

Cancer statistics, 2016

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

Targeting the EGFR signaling pathway in cancer therapy.

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Development of antigen-specific ELISA for circulating autoantibodies to extracellular matrix protein 1 in lichen sclerosus

P304

72447-72456

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.19785

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Eva Szabo

P577

2017-08-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29069801

http://www.w3.org/2001/XMLSchema#string

P932

5641144

http://www.w3.org/2001/XMLSchema#string

Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer.

about

P2860

P2860

Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932